However, when we tested two of these compounds, ABT-263 and ABT-737, well-known anti-cancer agents inhibiting the bcl2 family of anti-apoptotic proteins, we failed in killing p16Ink4a-overexpressing murine sarcomas. The gene discussed is BCL2; the disease is sarcoma.